Left Atrial Appendage Occlusion for The Unmet Clinical Needs of Stroke Prevention in Nonvalvular Atrial Fibrillation

David Holmes, Mohamad Alkhouli, Vivek Reddy

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

Oral anticoagulation is the dominant strategy for stroke prevention in patients with nonvalvular atrial fibrillation. However, lifelong oral anticoagulation is associated with major issues including inappropriate dosing, nonadherence, and adverse effects. Therefore, efforts have been made to develop site-specific therapy aimed to occlude the left atrial appendage, the anatomical site accountable for more than 90% of nonvalvular atrial fibrillation–related ischemic strokes. This review focuses on the growing literature to put into perspective the risk-balance ratio of left atrial appendage occlusion.

Original languageEnglish (US)
Pages (from-to)864-874
Number of pages11
JournalMayo Clinic proceedings
Volume94
Issue number5
DOIs
StatePublished - May 1 2019

Fingerprint

Atrial Appendage
Atrial Fibrillation
Stroke
Odds Ratio
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Left Atrial Appendage Occlusion for The Unmet Clinical Needs of Stroke Prevention in Nonvalvular Atrial Fibrillation. / Holmes, David; Alkhouli, Mohamad; Reddy, Vivek.

In: Mayo Clinic proceedings, Vol. 94, No. 5, 01.05.2019, p. 864-874.

Research output: Contribution to journalReview article

@article{4cec2ea8c5d74dc18edae2cae60f2dc2,
title = "Left Atrial Appendage Occlusion for The Unmet Clinical Needs of Stroke Prevention in Nonvalvular Atrial Fibrillation",
abstract = "Oral anticoagulation is the dominant strategy for stroke prevention in patients with nonvalvular atrial fibrillation. However, lifelong oral anticoagulation is associated with major issues including inappropriate dosing, nonadherence, and adverse effects. Therefore, efforts have been made to develop site-specific therapy aimed to occlude the left atrial appendage, the anatomical site accountable for more than 90{\%} of nonvalvular atrial fibrillation–related ischemic strokes. This review focuses on the growing literature to put into perspective the risk-balance ratio of left atrial appendage occlusion.",
author = "David Holmes and Mohamad Alkhouli and Vivek Reddy",
year = "2019",
month = "5",
day = "1",
doi = "10.1016/j.mayocp.2018.09.025",
language = "English (US)",
volume = "94",
pages = "864--874",
journal = "Mayo Clinic Proceedings",
issn = "0025-6196",
publisher = "Elsevier Science",
number = "5",

}

TY - JOUR

T1 - Left Atrial Appendage Occlusion for The Unmet Clinical Needs of Stroke Prevention in Nonvalvular Atrial Fibrillation

AU - Holmes, David

AU - Alkhouli, Mohamad

AU - Reddy, Vivek

PY - 2019/5/1

Y1 - 2019/5/1

N2 - Oral anticoagulation is the dominant strategy for stroke prevention in patients with nonvalvular atrial fibrillation. However, lifelong oral anticoagulation is associated with major issues including inappropriate dosing, nonadherence, and adverse effects. Therefore, efforts have been made to develop site-specific therapy aimed to occlude the left atrial appendage, the anatomical site accountable for more than 90% of nonvalvular atrial fibrillation–related ischemic strokes. This review focuses on the growing literature to put into perspective the risk-balance ratio of left atrial appendage occlusion.

AB - Oral anticoagulation is the dominant strategy for stroke prevention in patients with nonvalvular atrial fibrillation. However, lifelong oral anticoagulation is associated with major issues including inappropriate dosing, nonadherence, and adverse effects. Therefore, efforts have been made to develop site-specific therapy aimed to occlude the left atrial appendage, the anatomical site accountable for more than 90% of nonvalvular atrial fibrillation–related ischemic strokes. This review focuses on the growing literature to put into perspective the risk-balance ratio of left atrial appendage occlusion.

UR - http://www.scopus.com/inward/record.url?scp=85063911806&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063911806&partnerID=8YFLogxK

U2 - 10.1016/j.mayocp.2018.09.025

DO - 10.1016/j.mayocp.2018.09.025

M3 - Review article

C2 - 30962008

AN - SCOPUS:85063911806

VL - 94

SP - 864

EP - 874

JO - Mayo Clinic Proceedings

JF - Mayo Clinic Proceedings

SN - 0025-6196

IS - 5

ER -